These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9708526)

  • 21. Cisapride versus placebo in reflux esophagitis. A multicenter double-blind trial.
    Baldi F; Bianchi Porro G; Dobrilla G; Iascone C; Lobello R; Marzio L; Sabbatini F; Tittobello A; Verme G
    J Clin Gastroenterol; 1988 Dec; 10(6):614-8. PubMed ID: 3068300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride.
    Snape WJ
    Am J Manag Care; 1997 May; 3(5):766-71. PubMed ID: 10184748
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of two dosing regimens of cisapride in the treatment of reflux oesophagitis.
    Schütze K; Bigard MA; Van Waes L; Hinojosa J; Bedogni G; Hentschel E
    Aliment Pharmacol Ther; 1997 Jun; 11(3):497-503. PubMed ID: 9218072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease.
    Goldin GF; Marcinkiewicz M; Zbroch T; Bityutskiy LP; McCallum RW; Sarosiek J
    Dig Dis Sci; 1997 Jul; 42(7):1362-9. PubMed ID: 9246029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A case of bronchial asthma associated with reflux esophagitis, whose peak expiratory flow rate improved with omeprazole and cisapride].
    Fujimori K; Suzuki E; Arakawa M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1994 Nov; 32(11):1088-93. PubMed ID: 7815763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salivary secretion in reflux esophagitis.
    Sonnenberg A; Steinkamp U; Weise A; Berges W; Wienbeck M; Rohner HG; Peter P
    Gastroenterology; 1982 Oct; 83(4):889-95. PubMed ID: 7106518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Healing and prevention of relapse of reflux oesophagitis by cisapride.
    Toussaint J; Gossuin A; Deruyttere M; Hublé F; Devis G
    Gut; 1991 Nov; 32(11):1280-5. PubMed ID: 1752455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nizatidine and cisapride enhance salivary secretion in humans.
    Adachi K; Ono M; Kawamura A; Yuki M; Fujishiro H; Kinoshita Y
    Aliment Pharmacol Ther; 2002 Feb; 16(2):297-301. PubMed ID: 11860413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reflux esophagitis: therapeutic indications].
    Cloarec D; Bruley des Varannes S; Galmiche JP
    Rev Prat; 1988 Feb; 38(4):237-48. PubMed ID: 2895495
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of age and salivation in acid clearance in symptomatic patients with gastro-oesophageal reflux disease.
    Orr WC; Chen CL; Sloan S
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1385-8. PubMed ID: 11552909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences in salivary secretion and epidermal growth factor concentrations in mild reflux esophagitis and non-erosive reflux disease.
    Koeda M; Momma E; Tanabe T; Kitasako Y; Hoshikawa Y; Hoshino S; Kawami N; Iwakiri K
    Esophagus; 2023 Apr; 20(2):317-324. PubMed ID: 36344779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gastroesophageal scintigraphy following gastrectomy: comparison to endoscopy and esophageal biopsy.
    Fujiwara Y; Nakagawa K; Kuroki T; Kusunoki T; Utsunomiya J
    Am J Gastroenterol; 1993 Aug; 88(8):1233-6. PubMed ID: 8338091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
    Castell DO; Sigmund C; Patterson D; Lambert R; Hasner D; Clyde C; Zeldis JB
    Am J Gastroenterol; 1998 Apr; 93(4):547-52. PubMed ID: 9576446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cisapride versus ranitidine in reflux esophagitis].
    Janisch HD
    Z Gastroenterol; 1990 Apr; 28 Suppl 1():67-9; discussion 77-8. PubMed ID: 2192508
    [No Abstract]   [Full Text] [Related]  

  • 35. Decreased salivary function in patients with end-stage renal disease requiring hemodialysis.
    Kao CH; Hsieh JF; Tsai SC; Ho YJ; Chang HR
    Am J Kidney Dis; 2000 Dec; 36(6):1110-4. PubMed ID: 11096033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Healing of grade-II and III oesophagitis through motility stimulation with cisapride.
    Lepoutre L; Van der Spek P; Vanderlinden I; Bollen J; Laukens P
    Digestion; 1990; 45(2):109-14. PubMed ID: 2190850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.
    McKenna CJ; Mills JG; Goodwin C; Wood JR
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):817-22. PubMed ID: 8574711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prokinetic therapy in gastroesophageal reflux disease.
    Champion MC
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():55B-65B. PubMed ID: 9347180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative evaluation of salivary gland scintigraphy in Sjörgen's syndrome.
    Umehara I; Yamada I; Murata Y; Takahashi Y; Okada N; Shibuya H
    J Nucl Med; 1999 Jan; 40(1):64-9. PubMed ID: 9935059
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative salivary gland scintigraphy.
    Klutmann S; Bohuslavizki KH; Kröger S; Bleckmann C; Brenner W; Mester J; Clausen M
    J Nucl Med Technol; 1999 Mar; 27(1):20-6. PubMed ID: 10322570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.